Algenix, Inc. Information

Algenex is a biotechnology company backed by Cleon Capital and Columbus Venture Partners developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex first two platforms, TopBac® and CrisBio®, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate linear scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient. The Company's technology is highly applicable across a wide range of commercial product classes in both human and animal health. Algenex has successfully produced 200 molecules in collaboration with public and private partners, including multiple international pharmaceutical companies, including VLPs, monomeric vaccines, single domain antibodies, hormones, enzymes, growth factors and diagnostic reagents.